Myovant Sciences Announces Preliminary Financial Results for Third Quarter of Fiscal Year 2021

NEXT STORY
Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
PREV STORY
Codex DNA Signs Early Access Collaboration and Licensing Agreement with Pfizer to Further Develop Codex DNA’s Novel Enzymatic DNA Synthesis Technology for Pfizer’s use in its Research and Development of mRNA-based Vaccines and Biotherapies
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

EyePoint Pharmaceuticals Signs Exclusive License Agreement with Equinox Science to Develop Tyrosine Kinase Inhibitor Vorolanib for the Treatment of Wet AMD, Diabetic Retinopathy and Retinal Vein Occlusion

author_avatar
NASDAQ Market News

Genmab Announces European Marketing Authorization for the Subcutaneous Formulation of DARZALEX® (daratumumab) for the Treatment of Patients with Multiple Myeloma

author_avatar
NASDAQ Market News

CEPI Awards $25 Million Contract to Profectus BioSciences and Emergent BioSolutions to Develop Nipah Virus Vaccine

OSLO, Norway and BALTIMORE and GAITHERSBURG, Md., May 24, 2018 (GLOBE NEWSWIRE) -- CEPI—the ...

author_avatar
NASDAQ Market News